New drugs for Migraine

Gepants (CGRP receptor antagonists)
Names: Rimegepant (Nurtec ODT), Ubrogepant (Ubrelvy)


Mechanism: Block calcitonin gene-related peptide (CGRP) receptors, reducing inflammation and pain. –

Dosage:
Rimegepant: 75 mg orally as needed for acute migraine. – Ubrogepant: 50–100 mg orally as needed for acute migraine. –

Rationale: Effective for moderate to severe migraines, with fewer side effects than triptans. –

2. Ditans (Serotonin 5-HT1F receptor agonists)


Name: Lasmiditan (Reyvow)
Mechanism: Activates 5-HT1F receptors, reducing pain without vasoconstriction. – Dosage: 50–200 mg orally as needed for acute migraine. –

Rationale: Alternative for patients who cannot use triptans due to cardiovascular risks. –

3. Lasmiditan (Reyvow)
Mechanism: Selective 5-HT1F receptor agonist, reducing pain without vasoconstriction. – Side Effects: Dizziness, fatigue, paresthesia, muscle weakness. – Rationale: Suitable for patients with cardiovascular risks, as it lacks vasoconstrictive effects. –

4. Rimegepant (Nurtec ODT)
Mechanism: CGRP receptor antagonist, reducing inflammation and pain. – Dosage: 75 mg orally as needed for acute migraine. – Side Effects: Nausea, dizziness, somnolence. – Rationale: Effective for moderate to severe migraines, with a good safety profile. –

5. Ubrogepant (Ubrelvy)
Mechanism: CGRP receptor antagonist, reducing inflammation and pain. – Dosage: 50–100 mg orally as needed for acute migraine. – Rationale: Effective for moderate to severe migraines


Posted

in

,

by

Tags: